Market Research Report
Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease
|Published by||GlobalData||Product code||576590|
|Published||Content info||72 Pages
Delivery time: 1-2 business days
|Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease|
|Published: October 3, 2017||Content info: 72 Pages||
Kidneys are highly specialized organs that maintain a stable internal environment of the body - referred to as homeostasis - by selectively excreting, retaining and secreting various substances according to specific needs. The kidneys serve a pivotal role in a number of basic physiological functions, including blood pressure control, salt and water homeostasis, blood cell production, acid-base balance, and calcium homeostasis.
Renal diseases are typically classified as either chronic or acute. CKD is asymptomatic at the early stages and often undiagnosed (Dousdampanis et al., 2012). CKD often exists alongside other conditions such as cardiovascular disease (CVD), diabetes and certain autoimmune diseases such as lupus. The risk of developing CKD increases with age.
Symptoms of renal diseases differ slightly between indications. Renal diseases are typically asymptomatic until relatively advanced renal failure is present. Pain is not a common symptom due to the lack of pain receptors in the kidney, except in some renal diseases that involve the ureter or the renal capsule, such as nephrolithiasis (kidney stones). In the early stages of renal disease, patients may only experience abnormalities in urine output or a presence of red blood cells and/or protein in the urine. In later stages, systemic symptoms may manifest, as well as signs of lost renal function, such as edema, fluid overload, electrolyte abnormalities and anemia.
Majority of marketed products for renal diseases are small molecules, which account for more than 95% of all products. There are only a small number of other molecule types - such as monoclonal antibodies (mAb) and proteins - available in the market.
The pipeline is highly diverse in terms of molecule type. Unlike the marketed products, the pipeline contains a wide range of other molecule types, including proteins, mAbs, synthetic peptides, cell therapies and vaccines. While small molecules account for majority of the marketed products, they only account for about 60% of the pipeline. This is partly due to the relatively large proportion of biologics.
Drug development for renal diseases has significantly lagged behind other therapy areas, and very few novel therapies have been approved in the last decade. The marketed pharmacotherapeutic treatments for renal diseases typically focus on controlling the risk factors and complications of renal failure. Treatments include anti-hypertensive agents, hormones, antibiotics, and systemic immunosuppressants.
The report "Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease" assesses first-in-class innovation in the renal diseases pipeline, highlighting key trends and emerging treatment classes.
Specifically, this report outlines -